Xeris Pharmaceuticals AI Stock Analysis
Xeris Pharmaceuticals (0A8E) AI Stock Analysis
Xeris Pharmaceuticals
(LSE:0A8E)
No summary available
Xeris Pharmaceuticals (0A8E) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $3.07B
- Dividend Yield
- ―
- Average Volume (3M)
- 4,491
- Price to Earnings (P/E)
- -416.1
- Beta (1Y)
- 0.96
- Revenue Growth
- 38.37%
- EPS Growth
- 63.43%
- Country
- UK
- Employees
- 435
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Xeris Pharmaceuticals Business Overview & Revenue Model
Company Description
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfo...
Xeris Pharmaceuticals Earnings Call Summary
The call was strongly positive, with record third-quarter revenue, substantial Recorlev growth, improving Gvoke prescription demand, continued KEVEYIS growth, higher Adjusted EBITDA and net income, strengthened intellectual property, and raised 2026 and 2030 revenue outlooks. The primary negative items were Gvoke net revenue being reduced by a $4 million one-time Medicaid gross-to-net adjustment, ongoing prior authorization requirements for Recorlev, and higher commercial and operating expenses.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full-year 2026, Xeris raised total revenue guidance to $395 million-$405 million, representing approximately 37% growth at the midpoint; gross margin guidance remains unchanged, with continued improvement versus prior year expected, R&D expenses are expected to increase approximately $15 million compared to 2025 versus the prior expectation of a $25 million increase, and SG&A is expected to increase approximately $60 million compared to 2025 versus the prior expectation of $50 million. Adjusted EBITDA grew from $34 million-$65 million through the first three quarters, and continued Adjusted EBITDA growth is expected through the remainder of the year. Beyond 2026, Xeris expects more than $1 billion in total revenue in 2030 versus its previous outlook of $750 million, sees Recorlev on a path to $1 billion in annual net revenue three to four years sooner than previously projected, and expects to initiate the XP-8121 Cornerstone phase III study by year-end, with top-line data expected in late 2028 and potential approval and launch in 2030; XP-8121 has peak sales potential of $1 billion-$3 billion.
Xeris Pharmaceuticals Risk Analysis
Xeris Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Xeris Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksXeris Pharmaceuticals Peers Comparison
Overall Rating
ADMA82.4Outperform
HRMY77Outperform
MNKD55Neutral
BCRX49Neutral
PHVS41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | $3.02B | 17.07 | 42.56% | ― | 6.26% | -10.51% | |
| 77Outperform | $1.94B | 10.63 | 18.55% | ― | 19.79% | -4.89% | |
| 55Neutral | $1.31B | -17.13 | 139.41% | ― | 31.74% | -344.30% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $1.93B | -5.52 | 94.36% | ― | 60.30% | -3028.57% | |
| 41Neutral | $2.27B | -10.54 | -67.76% | ― | ― | 2.74% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0A8E | Xeris Pharmaceuticals | 16.73 | 9.67 | 137.07% | |
| BCRX | BioCryst Pharmaceuticals | 7.50 | 0.57 | 8.23% | |
| MNKD | MannKind Corporation | 4.07 | -0.93 | -18.60% | |
| ADMA | ADMA Biologics Inc | 13.63 | -2.32 | -14.55% | |
| HRMY | Harmony Biosciences Holdings, Inc. | 33.01 | -0.30 | -0.90% | |
| PHVS | Pharvaris N.V. | 32.28 | 7.74 | 31.54% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
